Extract from *Aronia melanocarpa* fruits potentiates the inhibition of platelet aggregation in the presence of endothelial cells

Boguslawa Luzak¹, Jacek Golanski¹, Marek Rozalski², Urszula Krajewska², Beata Olas³, Cezary Watala¹

**Abstract**

**Introduction:** Some polyphenolic compounds extracted from *Aronia melanocarpa* fruits (AM) have been reported to be cardioprotective agents. In this study we evaluated the ability of AM extract to increase the efficacy of human umbilical vein endothelial cells (HUVECs) to inhibit platelet functions *in vitro*.

**Material and methods:** This study encompasses two models of monitoring platelet reactivity: optical aggregation and platelet degranulation (monitored as the surface CD62P expression) in PRP upon the stimulation with ADP.

**Results:** We observed that only at low concentrations (5 μg/ml) did AM extract significantly improve antiplatelet action of HUVECs towards ADP-activated platelets in the aggregation test.

**Conclusions:** It is concluded that the potentiating effect of AM extract on the endothelial cell-mediated inhibition of platelet aggregation clearly depends on the used concentrations of *Aronia*-derived active compounds. Therefore, despite these encouraging preliminary outcomes on the beneficial effects of AM extract polyphenols, more profound dose-effect studies should certainly be considered before the implementation of *Aronia*-originating compounds in antiplatelet therapy and the prevention of cardiovascular diseases.

**Key words:** *Aronia melanocarpa* (chokeberry), endothelial cells, platelet aggregation, polyphenols, platelet reactivity.

**Introduction**

A substantial body of epidemiological literature suggests that the regular consumption of foods rich in polyphenols may reduce the risk of coronary heart disease and stroke [1]. In recent years a number of dietary sources inhibiting platelet function have been reported, but so far, due to the rather confusing array of conflicting evidence, the exact relationship between diet and platelet function remains unresolved [2]. There are no literature reports on the modulation of endothelial cell (EC)-induced inhibition of platelet aggregation by polyphenolic compounds. The general aim of this work is to evaluate the ability of the extract from *Aronia melanocarpa* fruits (AM) to improve EC efficacy at inhibiting platelet functions monitored under *in vitro* conditions. Berries of *A. melanocarpa* (chokeberries) have all the major healthy attributes and show the highest content of phenolic...
compounds (mainly anthocyanins) among the various natural products studied to date [3]. Special interest concerns significant protective action of chokeberry extracts/compounds on the cardiovascular system, and indeed, preliminary clinical studies have confirmed such compounds to be useful [4]. It has been reported that phenols (anthocyanins) from the chokeberry decreased blood pressure, lowered plasma lipid concentration and peroxidation, and reduced blood platelet reactivity, which makes them potentially interesting pharmaceuticals for cardiovascular therapy [5, 6]. In our studies we observed that chokeberry extract may increase the antiplatelet action of human umbilical vein endothelial cells (HUVECs) after stimulation with ADP, and it is important to emphasize the significance of the dose-effect relationship of such interactions. We also tested some potential molecular mechanisms possibly determining such effects. However, further investigations are needed to fully explore the molecular mechanism(s) of such an alleviating influence of AM extract.

Material and methods

Reagents

The extract of *A. melanocarpa* was supplied by Agropharm SA (Poland). This extract contains ca. 60% total phenolics, including a minimum of 20% anthocyanins. ADP was from Chrono-Log (Havertown, PA USA). Reagents for flow cytometry studies and Vacutainer™ containing 0.105 M buffered sodium citrate were from Becton Dickinson (San Diego, CA, USA). 6-keto-prostaglandin F1α EIA Kit was from Cayman Chemical Company (Ann Arbour, MI, USA).

Blood collection

Blood was collected from 16 healthy donors (8 men and 8 women, with a mean age of 29.8 ±12.4 year) into a vacuum tube containing 0.105 M buffered sodium citrate. The blood was centrifuged for 6 min at 1100 rpm to obtain the platelet-rich plasma (PRP). The platelet count in PRP was adjusted to 2 × 10^8 platelets/ml prior to use in all experiments.

The study was performed under the guidelines of the Helsinki Declaration for human research and approved by the committee on the Ethics of Research in Human Experimentation at the Medical University of Lodz (No. RNN/13/07/KB).

Cell cultures

Human umbilical vein endothelial cells and all reagents needed for cell culture were purchased from Cascade Biologics (Portland, Oregon, USA). The HUVECs were cultured according to the manufacturer’s instructions and the cells underwent 2-10 passages. In platelet aggregation studies, the HUVECs were suspended in Medium 200 at decreasing cell counts and finally in PRP the amount of HUVECs was 9.9 × 10^3 cells/ml or 6.6 × 10^3 cells/ml or 3.3 × 10^3 cells/ml. In flow cytometry studies the HUVECs were first transferred to 24-well plates at the count of 75 × 10^3 cells per well and these cells were further grown in a humidified atmosphere of 5% CO2 in air at 37°C for 24 h.

Measurements of platelet reactivity

Aggregation

Platelet-rich plasma was incubated (10 min, 37°C) with AM (5, 10, 30 μg/ml) and/or HUVECs suspended in Medium 200 without supplements. As a control, Medium 200 was used. Platelet reactivity in the presence of 10 μM ADP was monitored for 10 min using a method of optical aggregation and the aggregation curves were analysed using Platelet Aggregation Monitoring and Analysis (PAMA) software [7].

Flow cytometry

Platelets in PRP were incubated with HUVEC on 24-well cluster dishes (10 min at 37°C). The incubation with *A. melanocarpa* extract (final concentrations 0, 5, 10, 20, 30 μg/ml, 10 min at 37°C) followed two patterns: 1) AM was added to the HUVECs in Medium 200; after 10-min incubation the culture medium was removed from the wells, and PRP (2 × 10^8 platelets/ml) was added (pre-incubation of HUVECs with AM); 2) AM and PRP were directly added to the HUVECs growing on the wells (without pre-incubation of HUVECs with AM). Optionally, 10 μM ADP was added to the platelet suspensions in the wells with HUVECs. After incubation, PRP was aspirated from wells, mixed and immediately fixed with CellFix (2 h at room temperature or overnight at 4°C). After that, platelet surface CD62P expression was analysed for 5000 platelets using BD LSR II System (Becton Dickinson, San Diego, CA, USA).

Measurements of prostacyclin

The concentrations of 6-keto-prostaglandin F1α, a stable metabolite of prostacyclin (PGI), were monitored in the aliquots of plasma obtained after platelet aggregation induced with ADP (following sample centrifugation at 10,000 rpm, 6 min, stored at −70°C until assayed) using EIA Kit.

Statistical analysis

Mean ± SEM is given for all parameters. Shapiro-Wilk test was used to verify whether the data were normally distributed and Student’s t-test for paired
data was employed to estimate the significance of differences, with Bonferroni correction for multiple comparisons, where needed.

Results

In the last few years there has been an increasing interest in screening substances, especially natural products from plants, which may stimulate endothelial cells to produce antplatelet modulators (prostacyclin [PGI] and nitric oxide [NO*]). Relevant to the topic of our study are the reports indicating that indirect effects of flavonoids on platelet inhibition may be dependent on endothelial cells. In our present study we have attempted to assess whether natural chokeberry extract (A. melanocarpa fruits) may further attenuate platelet reactivity in addition to the endothelial cell-mediated inhibition of platelet function. This study encompasses two simple models of monitoring platelet reactivity: platelet aggregation and platelet degranulation (monitored as the surface CD62P expression) in PRP upon the stimulation of platelets with exogenous ADP. We observed a significant reduction in ADP-induced platelet aggregation in the presence of HUVECs, an effect which depended on the cell count in the endothelial cell cultures (the rates of inhibition were 46.9 ±5.7% for 9.9 × 10³ cells/ml, 40.5 ±7.1% for 6.6 × 10³ cells/ml and 36.3 ±2.8% for 3.3 × 10³ cells/ml, respectively p < 0.001 or less). We also revealed a significant reduction in CD62P (P-selectin) expression on the surface of ADP-induced platelets after incubation with HUVECs (the expression was 40.7 ±3.5 vs. 29.6 ±3.2% for control without EC and for platelets with EC respectively, p < 0.001). Thus, our observations are consistent with those of other studies reporting reduced blood platelet reactivity by endothelial cells [8, 9].

To further monitor the expected intensifying effect of the chokeberry extract on inhibiting platelet reactivity in the presence of HUVECs, we finally used the culture with 3.3 × 10³ cells/ml. Significance of differences estimated with paired Student’s t-test with Bonferroni correction for multiple comparisons. AM in 5 µg/ml concentration significantly reduced platelet aggregation in the presence of EC (*p < 0.05).

Table I. The inhibition of ADP-induced platelet reactivity by Aronia melanocarpa extract (AM) in the presence of endothelial cells

<table>
<thead>
<tr>
<th>Concentration of AM [µg/ml]</th>
<th>Aggregation (n)</th>
<th>CD62P expression (not pre-incubated with AM)</th>
<th>CD62P expression (pre-incubated with AM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>36.3 ±2.8 (n = 11)</td>
<td>27.5 ±3.7 (n = 14)</td>
<td>25.3 ±2.6 (n = 11)</td>
</tr>
<tr>
<td>5</td>
<td>43.3 ±3.6 (n = 10)*</td>
<td>24.9 ±6.1 (n = 10)</td>
<td>24.9 ±3.3 (n = 10)</td>
</tr>
<tr>
<td>10</td>
<td>35.3 ±3.5 (n = 10)</td>
<td>21.3 ±5.1 (n = 12)</td>
<td>28.3 ±2.9 (n = 11)</td>
</tr>
<tr>
<td>20</td>
<td>36.0 ±4.7 (n = 7)</td>
<td>24.2 ±4.9 (n = 12)</td>
<td>26.2 ±3.8 (n = 11)</td>
</tr>
<tr>
<td>30</td>
<td>37.8 ±3.4 (n = 9)</td>
<td>13.4 ±6.4 (n = 12)</td>
<td>28.3 ±4.2 (n = 11)</td>
</tr>
</tbody>
</table>

The extent of the inhibition of platelet reactivity calculated vs ADP-induced aggregation or CD62P expression for ADP-activated samples. EC count was 3.3 × 10³ cells/ml. Significance of differences estimated with paired Student’s t-test with Bonferroni correction for multiple comparisons. AM in 5 µg/ml concentration significantly reduced platelet aggregation in the presence of EC (*p < 0.05).
In our study we have observed a significantly increased concentration of 6-keto prostaglandin F$_{1\alpha}$ (a stable metabolite of prostacyclin) in plasma after ADP-induced platelet aggregation in the presence of HUVECs (400.2 ±94.4 pg/ml for PRP with EC vs. 55.1 ±22.1 pg/ml for PRP without EC, p < 0.05). Nevertheless, the presence of AM extract did not significantly enhance the increase of 6-keto PGF$_{1\alpha}$ concentration. These data may suggest that the antiplatelet effect of EC in the presence of low concentrations of AM is most likely not mediated by PGI generation. Even though these results neither provide convincing evidence for revealing the mechanisms of an indirect antiplatelet action of AM, nor explore the mechanisms of AM–EC interaction(s), they certainly do encourage further investigations of this problem.

In conclusion, the results of our work support the concept that modulation and improvement of endothelial function with preparations of herbal origin (food supplements) may be beneficial in hampering exaggerated blood platelet reactivity. Importantly, the potentiating effect of AM extract on the endothelial cell-mediated inhibition of platelet aggregation is clearly concentration-dependent. Hence despite these encouraging preliminary outcomes on beneficial effects of AM extract polyphenols, more profound dose-effect studies should certainly be considered before implementing Aronia-derived extracts in antiplatelet therapy and the prevention of cardiovascular diseases.

Acknowledgments

This study was supported by project N405 065034 of the Polish Ministry of Science and Higher Education, grant 502-16-651 from the Medical University of Lodz.

References